Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Dyax Corporation Genzyme Dyax-Genzyme LLC |
---|---|
Information provided by: | Dyax Corporation |
ClinicalTrials.gov Identifier: | NCT00262080 |
The purpose of this study is to determine if a subcutaneous dose of DX-88 (an investigational product) is safe and relieves symptoms of HAE in patients suffering from moderate to severe attacks.
Condition | Intervention | Phase |
---|---|---|
Hereditary Angioedema (HAE) |
Drug: DX-88 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Double-Blind, Placebo-Controlled Study Followed by a Repeat Dosing Phase to Assess the Efficacy and Safety of DX-88 (Recombinant Plasma Kallikrein Inhibitor) for the Treatment of Acute Attacks of Hereditary Angioedema |
Ages Eligible for Study: | 10 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | EDEMA3 (DX-88/14) |
Study First Received: | December 5, 2005 |
Last Updated: | October 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00262080 |
Health Authority: | United States: Food and Drug Administration |
Hypersensitivity Kallikreins Genetic Diseases, Inborn Skin Diseases Angioedema |
Hypersensitivity, Immediate Vascular Diseases Urticaria Angioedema, Hereditary Hereditary angioedema |
Skin Diseases, Vascular Immune System Diseases Cardiovascular Diseases |